Literature DB >> 25445397

Biallelic inactivation of protoporphyrinogen oxidase and hydroxymethylbilane synthase is associated with liver cancer in acute porphyrias.

Xiaoye Schneider-Yin1, Anne-Moon van Tuyll van Serooskerken2, Marko Siegesmund3, Philip Went4, Jasmin Barman-Aksözen1, Reno S Bladergroen2, Paul Komminoth5, Roy H E Cloots6, Véronique J Winnepenninckx6, Axel zur Hausen6, Markus Weber7, Ann Driessen6, Pamela Poblete-Gutiérrez8, Peter Bauer9, Christopher Schroeder9, Michel van Geel2, Elisabeth I Minder1, Jorge Frank10.   

Abstract

Variegate porphyria (VP) and acute intermittent porphyria (AIP), the two most common types of acute porphyrias (AHPs), result from a partial deficiency of protoporphyrinogen oxidase (PPOX) and hydroxymethylbilane synthase (HMBS), respectively. A rare but serious complication in the AHPs is hepatocellular carcinoma (HCC). However, the underlying pathomechanisms are yet unknown. We performed DNA sequence analysis in cancerous and non-cancerous liver tissue of a VP and an AIP patient, both with HCC. In samples of both cancerous and non-cancerous liver tissues from the patients, we identified the underlying PPOX and HMBS germline mutations, c.1082dupC and p.G111R, respectively. Additionally, we detected a second somatic mutation, only in the cancer tissue i.e., p.L416X in the PPOX gene of the VP patient and p.L220X in the HMBS gene of the AIP patient, both located in trans to the respective germline mutations. Both somatic mutations were not detected in 10 non-porphyria-associated HCCs. Our data demonstrate that in the hepatic cancer tissue of AHP patients, somatic second-hit mutations result in nearly complete inactivation of the enzymes catalyzing major steps in the heme biosynthetic pathway. Both PPOX and HMBS, which might act as tumor suppressors, play a crucial role in the development of HCC in these individuals.
Copyright © 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute intermittent porphyria; Hepatocellular carcinoma; Tumor suppressor; Variegate porphyria

Mesh:

Substances:

Year:  2014        PMID: 25445397     DOI: 10.1016/j.jhep.2014.11.029

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  6 in total

Review 1.  The acute hepatic porphyrias.

Authors:  Bruce Wang
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

Review 2.  The association between chemical-induced porphyria and hepatic cancer.

Authors:  Andrew G Smith; John R Foster
Journal:  Toxicol Res (Camb)       Date:  2018-06-01       Impact factor: 3.524

3.  Multi-omics data integration for hepatocellular carcinoma subtyping with multi-kernel learning.

Authors:  Jiaying Wang; Yuting Miao; Lingmei Li; Yongqing Wu; Yan Ren; Yuehua Cui; Hongyan Cao
Journal:  Front Genet       Date:  2022-09-06       Impact factor: 4.772

4.  Prediction of Chlamydia pneumoniae protein localization in host mitochondria and cytoplasm and possible involvements in lung cancer etiology: a computational approach.

Authors:  Aws Alshamsan; Shahanavaj Khan; Ahamad Imran; Ibrahim A Aljuffali; Khalid Alsaleh
Journal:  Saudi Pharm J       Date:  2017-05-31       Impact factor: 4.330

5.  Identification of Diagnostic Biomarkers and Subtypes of Liver Hepatocellular Carcinoma by Multi-Omics Data Analysis.

Authors:  Xiao Ouyang; Qingju Fan; Guang Ling; Yu Shi; Fuyan Hu
Journal:  Genes (Basel)       Date:  2020-09-06       Impact factor: 4.096

6.  Risk of primary liver cancer in acute hepatic porphyria patients: A matched cohort study of 1244 individuals.

Authors:  Mattias Lissing; Daphne Vassiliou; Ylva Floderus; Pauline Harper; Matteo Bottai; Marianna Kotopouli; Hannes Hagström; Eliane Sardh; Staffan Wahlin
Journal:  J Intern Med       Date:  2022-03-02       Impact factor: 13.068

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.